| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The specific target for OVA (329-337) is the MHC class II molecule I-Aᵈ in BALB/c mice. The peptide is presented by MHC class II on the surface of antigen-presenting cells to the T cell receptor (TCR) of specific CD4+ T cell clones (e.g., DO11.10 or OT-II).
|
|---|---|
| ln Vitro |
In DO11.10 and OT-II cells, OVA (329–339) stimulates proliferation to half-maximum at 25 μM and 30 μM, respectively[1].
In vitro, OVA (329-337) acts as a potent stimulator of CD4+ T cell proliferation. The peptide activates T cell hybridomas and primary T cell lines isolated from OVA-immunized mice. It induces half-maximal proliferation in DO11.10 and OT-II cells at concentrations of approximately 25 microM and 30 microM, respectively, demonstrating its function as a specific T cell epitope. |
| ln Vivo |
In vivo, OVA (329-337) is used to stimulate T cell-mediated immune responses in animal models. When administered subcutaneously in an adjuvant (e.g., CFA), it can induce T cell activation and proliferation in OVA-specific T cell receptor transgenic mice. It is also commonly used in adoptive transfer models to track antigen-specific T cell responses.
|
| Enzyme Assay |
A direct non-cellular binding assay is used to measure MHC-peptide affinity. Soluble I-Aᵈ MHC class II molecules are incubated with varying concentrations of fluorescently-labeled OVA (329-337) peptide. After equilibration, the bound vs. free peptide is separated by size exclusion chromatography, and fluorescence is measured to calculate the dissociation constant (Kd).
|
| Cell Assay |
The standard cellular assay measures T cell proliferation. Splenocytes or lymph node cells from DO11.10 transgenic mice (which express a TCR specific for OVA (329-337)) are cultured in 96-well plates. Varying concentrations of OVA (329-337) peptide (typically 0-100 microM) are added to the cells. After 48-72 hours, proliferation is measured by adding 3H-thymidine or using a colorimetric method (e.g., MTT). Results are expressed as a stimulation index (fold increase over unstimulated controls).
|
| Animal Protocol |
To evaluate in vivo T cell activation, mice are immunized subcutaneously at the base of the tail. OVA (329-337) peptide (100 microg) is emulsified in Complete Freund‘s Adjuvant (CFA). After 7-10 days, draining lymph nodes (inguinal/periaortic) are harvested. Single-cell suspensions are prepared and restimulated ex vivo with the peptide. T cell activation is assessed by measuring proliferation (3H-thymidine) or cytokine production (e.g., IFN-gamma by ELISA).
|
| ADME/Pharmacokinetics |
As a peptide epitope, pharmacokinetic properties are not typically characterized for this reagent. Its primary use is as an in vitro reagent. After subcutaneous injection, it is rapidly distributed to the lymph nodes, processed by antigen-presenting cells, and loaded onto MHC II molecules. The free peptide is degraded by tissue peptidases within minutes to hours.
|
| Toxicity/Toxicokinetics |
OVA (329-337) is not a cytotoxic compound. It is a highly specific immune stimulator that induces T cell activation and proliferation. Toxic effects are not associated with the peptide itself at standard research concentrations (0.1-100 microM), but the resulting immune response (if used in vivo with adjuvant) can lead to inflammation at the injection site.
|
| References |
[1]. J M Robertson, et al. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol. 2000 May 1;164(9):4706-12.
|
| Additional Infomation |
OVA (329-337) is a core epitope used extensively in immunological research as a model antigen for studying MHC class II-restricted antigen presentation and CD4+ T cell activation. Its sequence is AAHAEINEA. It has no therapeutic application or drug approval status; it is strictly a laboratory research tool for studying basic immunology.
|
| Molecular Formula |
C38H60N12O15
|
|---|---|
| Molecular Weight |
924.95
|
| Exact Mass |
924.43
|
| CAS # |
276889-40-8
|
| PubChem CID |
168008664
|
| Appearance |
Colorless to off-white solid powder
|
| LogP |
-6.5
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
65
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)NC(=O)[C@H](C)N
|
| InChi Key |
WDUIVGVJPMWQBK-DACHUPBLSA-N
|
| InChi Code |
InChI=1S/C38H60N12O15/c1-7-16(2)29(37(63)49-25(13-26(40)51)36(62)47-22(8-10-27(52)53)33(59)45-20(6)38(64)65)50-34(60)23(9-11-28(54)55)46-31(57)19(5)44-35(61)24(12-21-14-41-15-42-21)48-32(58)18(4)43-30(56)17(3)39/h14-20,22-25,29H,7-13,39H2,1-6H3,(H2,40,51)(H,41,42)(H,43,56)(H,44,61)(H,45,59)(H,46,57)(H,47,62)(H,48,58)(H,49,63)(H,50,60)(H,52,53)(H,54,55)(H,64,65)/t16-,17-,18-,19-,20-,22-,23-,24-,25-,29-/m0/s1
|
| Chemical Name |
(4S)-5-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxyethyl]amino]-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: < 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0811 mL | 5.4057 mL | 10.8114 mL | |
| 5 mM | 0.2162 mL | 1.0811 mL | 2.1623 mL | |
| 10 mM | 0.1081 mL | 0.5406 mL | 1.0811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
